Abstracts tagged "Biologic agents and rheumatoid arthritis (RA)"

Abstract Number: 1466 • 2013 ACR/ARHP Annual Meeting
Survival On Treatment Of The Second Line Biologic Therapy: Switch Or Swap Strategy?
Ennio G. Favalli¹, Martina Biggioggero², Antonio Marchesoni³ and Pier Luigi Meroni², ¹Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, Milan, Italy, ²Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, ³UOC Day Hospital Rheumatology, Gaetano Pini Institute, Milan, Italy, Milano, Italy
Background/Purpose: The strategy for the choice of the second biologic agent after the failure of the first TNF inhibitor is still an unclear aspect in…
Abstract Number: 501 • 2013 ACR/ARHP Annual Meeting
A Randomized Placebo-Controlled Phase 2 Study To Evaluate Efficacy, Safety and Tolerability Of Two Secukinumab Loading Dose Regimens In Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate
Silvano Adami¹, André Beaulieu², Proton Rahman³, Bruno Seriolo⁴, Janet S. Lee⁵, Gerhard Krammer⁶, Brian Porter⁵, Anuradha Thulasiraman⁶ and Hanno B. Richards⁷, ¹Rheumatology Department, University of Verona, Verona, Italy, ²Faculty of Medicine, Laval University, Quebec, QC, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁵Novartis Pharma AG, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
A Randomized Placebo-Controlled Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Two Secukinumab Loading Dose Regimens in Subjects with Active Rheumatoid Arthritis Despite…